Atea Pharmaceuticals (AVIR) Total Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 15.54% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 15.54% YoY), while the FY2025 annual figure was $39.8 million, up 54.2% from the prior year.
• Total Liabilities was $33.4 million for Q1 2026 at Atea Pharmaceuticals, down from $39.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $48.7 million in Q1 2024 to a low of $19.9 million in Q1 2023.
• Historically, Total Liabilities has averaged $31.0 million across 5 years, with a median of $28.9 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities tumbled 91.07% in 2022, then surged 143.91% in 2024.
• A 5-year view of Total Liabilities shows it stood at $26.1 million in 2022, then surged by 52.19% to $39.8 million in 2023, then sank by 35.13% to $25.8 million in 2024, then soared by 54.2% to $39.8 million in 2025, then dropped by 16.13% to $33.4 million in 2026.
• The last three Total Liabilities figures came in at $33.4 million (Q1 2026), $39.8 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.